Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 removed in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedFooter branding updates add 'Moffitt Cancer Center Clinical Trials website' and 'Helpful Links Provided by', and a government funding status notice was removed from the page.SummaryDifference0.6%

- Check34 days agoChange DetectedCore study details appear unchanged; no additions or deletions to the main study information were detected. The overall page structure and key fields such as title, conditions, interventions, outcomes, and eligibility remain the same.SummaryDifference0.4%

- Check63 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference3%

- Check70 days agoChange DetectedUpdated metadata to reflect a newer version (v3.1.0) and more current dates (2025-09) while removing older metadata (v3.0.2, 2025-05). This signals an updated release cycle and recentness without clear changes to core content.SummaryDifference0.7%

- Check84 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.